Immunotherapy

• 2-Year ZUMA-1 Results Add Support For Axicabtagene Ciloleucel In Refractory Large B-Cell Lymphoma
• How to manage toxicities from Immune Checkpoint Inhibitors?
• Adjuvant treatment for colon cancer: How to treat a stage III colon cancer?
• Adjuvant treatment for colon cancer: How to treat a T3N0M0 colon cancer?
• How to use Neoadjuvant Therapies in Breast Cancer?
• High Response Rates With Tisagenlecleucel In Adult Refractory DLBCL Patients
• Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): safety and clinical activity results from a Phase Ib study
• Immunotherapy vs. targeted therapy in first-line treatment of mutation positive metastatic melanomas: How does one choose?
• Hyperprogression following immunotherapy: Myth or reality?
• Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: results from the KEYNOTE-407 East Asia...
• Is there some hope from immunotherapy in metastatic gastric cancer?
• The survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors
• PD-L1 expression and clinical outcome after nivolumab monotherapy in various subtypes of melanoma: a single-institutional retrospective study
• Stage III NSCLC and the immuno-oncology paradigm: Radiotherapy considerations
• Concurrent nivolumab and radiotherapy in treatment of lung squamous cell carcinoma
• The long term survival of a 78 year old female diagnosed with Malignant Epithelial Mesothelioma with peritoneal disease on Pembrolizumab plus Pemet...
• Nivolumab Induced Immune Thrombocytopenia in a patient with Relapsed Carcinoma of Tongue
• Local disease control of nasal malignant melanoma achieved by administration of nivolumab followed by palliative radiation: a case report
• Excellent response of nivolumab in patient with metastatic malignant melanoma of vagina: a case report
• GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemoth...
• Real World Experience of adverse events with immunotherapy using PD1 inhibitors- Single center experience from India
• A Phase 1 trial of the safety and pharmacokinetics of cemiplimab, a human monoclonal antibody to programmed death-1, in Japanese patients with adva...
• Phase 2 KEYNOTE-164 Study of Pembrolizumab (pembro) Monotherapy for Patients (pts) With Previously Treated, Mismatch Repair–Deficient (dMMR) Advanc...
• Response to Multi-Targeted Kinase Inhibitor (MKI) after Immune Checkpoint Inhibitor (ICI) in Patients with Hepatocellular Carcinoma (HCC)
• A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr Virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated mali...

• « Previous
• 1
• 2
• ...
• 87
• Next »